Compare StocksABBV vs NOC

AbbVie Inc. (ABBV) vs Northrop Grumman Corporation (NOC): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. NOC is fairly valued at $522, with an intrinsic value of $531 and a margin of safety of 2%. Of the two, NOC has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
NOC
Northrop Grumman Corporation
$521.50

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
NOC
  • Free cash flow has grown at a 31.1% CAGR over the past 4 years, demonstrating strong earnings power growth.
  • Trailing P/E of 16.3x is 26% below the historical average of 22.0x — potentially undervalued relative to its own history.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
  • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
NOC
  • Gross margin of 20.5% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • PEG ratio of 4.11 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • 18 insider sales with no purchases over the past 12 months — a persistent pattern of insider selling.

Key Valuation Metrics

Learn more →
ABBV
NOC
Valuation
$20.81B
Free Cash Flow
$3.31B
5.44%
FCF Yield
4.46%
105.60
Trailing P/E
16.34
13.32
Forward P/E
17.30
Quality & Moat
21.89%
ROIC
11.28%
N/A
ROE
28.51%
72.03%
Gross Margin
20.52%
0.61
PEG Ratio
4.11
Balance Sheet Safety
N/A
Net Debt / Equity
0.90
N/A
Interest Coverage
N/A
2.12
Net Debt / EBITDA
2.12
3.11%
Dividend Yield
1.71%
ABBV: 7Ties: 2NOC: 1
ABBVNOC

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

NOC

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
NOC
$-0.38
created per $1 retained over 3 years
Market Cap Declined
Σ Retained
$6.82B
Δ Market Cap
$-2.60B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
35.3% Overvalued
Price is 35.3% above estimated fair value
Current Price: $216.49
Fair Value: $160.05
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
NOC
1.8% Margin of Safety
Price is 1.8% below estimated fair value
Current Price: $521.50
Fair Value: $531.22
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

What growth rate is the market pricing in at $216?

+17.1%
Market-Implied Owner Earnings Growth
Standard FCF implies +8.7%

The market implies +17.1% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

NOC

What growth rate is the market pricing in at $522?

+8.6%
Market-Implied Owner Earnings Growth
Standard FCF implies +11.8%

The market implies +8.6% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +11.8%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
NOC
68/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with revenue predictability as the key competitive advantage. Improving margin stability would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
NOC
-2.45
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,106
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
NOC
Insiders 0.2%Institutions 84.4%Retail & Other 15.4%
No. of Institutional Holders2,307
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
NOC
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID R.
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
GONZALEZ RICHARD A
Officer and Director
$49.50M
@ $175.00 · 2024-07-17
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
NOC
1
Sells (3M)
18
Sells (12M)
Total value (12M): $26.77M
WELSH MARK A. III
Director
$54,310
@ $571.68 · 2026-05-04
SIMPSON KATHRYN G.
General Counsel
$650,385
@ $745.00 · 2026-03-02
ROEDER ROSHAN S.
Officer
$1.26M
@ $720.00 · 2026-02-27
ROEDER ROSHAN S.
Officer
$372,541
@ $727.62 · 2026-02-19
SIMPSON KATHRYN G.
General Counsel
$141,158
@ $727.62 · 2026-02-19
HARDESTY MICHAEL A
Officer
$107,748
@ $732.98 · 2026-02-19
DAVIES BENJAMIN R
Officer
$1.58M
@ $719.62 · 2026-02-18
ROEDER ROSHAN S.
Officer
$223,414
@ $702.56 · 2026-02-17
SIMPSON KATHRYN G.
General Counsel
$547,294
@ $702.56 · 2026-02-17
HARDESTY MICHAEL A
Officer
$501,609
@ $701.55 · 2026-02-17
HARDESTY MICHAEL A
Officer
$550,411
@ $702.95 · 2026-02-13
WARDEN KATHY J
Chief Executive Officer
$14.18M
@ $708.82 · 2026-02-06
WELSH MARK A. III
Director
$65,029
@ $684.52 · 2026-02-02
WARDEN KATHY J
Chief Executive Officer
$6.04M
@ $604.50 · 2026-01-06
ROEDER ROSHAN S.
Officer
$46,649
@ $555.35 · 2025-12-09
WELSH MARK A. III
Director
$54,716
@ $564.08 · 2025-11-24
JONES THOMAS H.
Officer
$382,725
@ $525.00 · 2025-07-17
WELSH MARK A. III
Director
$16,720
@ $506.67 · 2025-07-07
JONES THOMAS H.
Officer
$368,706
@ $505.77 · 2025-06-13
FLEMING ROBERT J
Officer
$1.77M
@ $505.77 · 2025-06-13
WARDEN KATHY J
Chief Executive Officer
$5.65M
@ $502.18 · 2025-06-13
WELSH MARK A. III
Director
$16,120
@ $488.48 · 2025-06-05
ROEDER ROSHAN S.
Officer
$485,590
@ $490.00 · 2025-06-04
JONES THOMAS H.
Officer
$349,920
@ $480.00 · 2025-05-30
WELSH MARK A. III
Director
$16,293
@ $493.73 · 2025-05-05
WELSH MARK A. III
Director
$15,850
@ $480.30 · 2025-04-07
WARDEN KATHY J
Chief Executive Officer
$1.78M
@ $475.65 · 2025-03-06
WELSH MARK A. III
Director
$15,631
@ $473.67 · 2025-03-05
DAVIES BENJAMIN R
Officer
$213,788
@ $460.75 · 2025-02-28
HARDESTY MICHAEL A
Officer
$875,873
@ $453.59 · 2025-02-24
SIMPSON KATHRYN G.
General Counsel
$444,098
@ $429.08 · 2025-02-20
DAVIES BENJAMIN R
Officer
$82,383
@ $429.08 · 2025-02-20
SIMPSON KATHRYN G.
General Counsel
$395,916
@ $445.35 · 2025-02-18
DAVIES BENJAMIN R
Officer
$130,488
@ $445.35 · 2025-02-18
WELSH MARK A. III
Director
$15,843
@ $480.09 · 2025-02-05
WELSH MARK A. III
Director
$15,072
@ $456.73 · 2025-01-06
WELSH MARK A. III
Director
$15,886
@ $481.39 · 2024-12-05
DAVIES BENJAMIN R
Officer
$616,067
@ $532.93 · 2024-11-11
WELSH MARK A. III
Director
$16,833
@ $510.09 · 2024-11-05
WELSH MARK A. III
Director
$17,675
@ $535.61 · 2024-10-07
WELSH MARK A. III
Director
$17,151
@ $519.73 · 2024-09-05
WELSH MARK A. III
Director
$17,546
@ $516.06 · 2024-08-29
JONES THOMAS H.
Officer
$695,000
@ $500.00 · 2024-08-02
JONES THOMAS H.
Officer
$1.30M
@ $469.25 · 2024-07-26
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😐Neutral(56/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
NOC
FearGreed
😨Fear(36/100)

"Market is pessimistic — investigate whether fears are temporary or structural"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
NOC
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Fear (36)
View ABBV Full AnalysisView NOC Full Analysis

Frequently Asked Questions: ABBV vs NOC

Is AbbVie Inc. or Northrop Grumman Corporation more undervalued in 2026?

Based on our discounted cash flow model, NOC trades at a 1.8% margin of safety (intrinsic value $531 vs. price $522), compared to ABBV's -35.3% margin of safety (intrinsic $160 vs. $216).

Which stock has a wider economic moat, AbbVie Inc. or Northrop Grumman Corporation?

ABBV scores 82/100 (Wide moat), while NOC scores 68/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. NOC scores 3.0 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, AbbVie Inc. or Northrop Grumman Corporation?

AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Northrop Grumman Corporation's 4.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, AbbVie Inc. or Northrop Grumman Corporation?

ABBV earns 21.9% ROIC versus NOC's 11.3%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Northrop Grumman Corporation's?

NOC's dividend earns a safety score of 94/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). NOC has raised its dividend for 3 consecutive years.